# Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
Canonical URL: https://biopharmsignal.com/news/IVA/statement-of-total-voting-rights-and-shares-forming-the-company-s-share-capital--1d9ce97c
Ticker: IVA
Company: Inventiva
Source: Inventiva
Published: 2026-06-09 20:00 EST
## Summary

Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site: www.inventivapharma.com...

## Article Body
Article R. 22-10-23 of the French Commercial Code

Market : Euronext Paris

ISIN code / Mnemo: FR0013233012 / IVA

Web site: www.inventivapharma.com

| Date | Number of Shares Outstanding | Total Voting Rights, Gross (1) | Total Voting Rights, Net (2) |
| --- | --- | --- | --- |
| May 22, 2026 | 209 007 475 | 218 082 368 | 218 082 368 |

The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed .

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com

Contacts

Inventiva - PR - Voting Rights - EN - 06 09 2026
## Recent Company News
- 2026-07-09 20:20 EST — [Inventiva annonce la finalisation de la restructuration des BSA BEI à la suite de l'émission des Nouveaux BSA BEI](https://biopharmsignal.com/news/IVA/inventiva-annonce-la-finalisation-de-la-restructuration-des-bsa-bei-la-suite-de--60ee4494) — Source: Inventiva
- 2026-07-09 20:20 EST — [Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants](https://biopharmsignal.com/news/IVA/inventiva-announces-completion-of-the-eib-warrant-restructuring-with-the-issuanc-ea832ac9) — Source: Inventiva
- 2026-07-02 20:00 EST — [Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 30 juin 2026](https://biopharmsignal.com/news/IVA/r-sultats-des-votes-de-l-assembl-e-g-n-rale-mixte-des-actionnaires-r-unie-le-30--623fc98c) — Source: Inventiva
- 2026-07-02 20:00 EST — [Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026](https://biopharmsignal.com/news/IVA/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-june-30-202-4542eebe) — Source: Inventiva
- 2026-06-12 20:00 EST — [Inventiva annonce le Remboursement des Prêts BEI, le Rachat d'une partie des BSA BEI et l'émission des deux premières tranches dans le cadre du Nouveau Financement](https://biopharmsignal.com/news/IVA/inventiva-annonce-le-remboursement-des-pr-ts-bei-le-rachat-d-une-partie-des-bsa--76c5faf3) — Source: Inventiva
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)